{"id":"azd8931","safety":{"commonSideEffects":[{"rate":"null","effect":"Diarrhoea"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL2408045","moleculeType":"Small molecule","molecularWeight":"473.94"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD8931 works by inhibiting the PI3K pathway, which is involved in cell growth and survival. This can help to slow or stop the growth of cancer cells.","oneSentence":"AZD8931 is a PI3K inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:25.818Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumours"}]},"trialDetails":[{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT02117167","phase":"PHASE2","title":"SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2014-04-23","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":999},{"nctId":"NCT01862003","phase":"PHASE2","title":"Phase I/II Trial of Antagonism of HER in GI Cancer","status":"COMPLETED","sponsor":"University College, London","startDate":"2014-05","conditions":"Metastatic Colorectal Cancer, Recurrent Colorectal Cancer","enrollment":24},{"nctId":"NCT00900627","phase":"PHASE1, PHASE2","title":"Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Neoplasms, Breast Neoplasms, Breast Cancer","enrollment":330},{"nctId":"NCT01579578","phase":"PHASE2","title":"Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2012-04","conditions":"Metastatic, Gastric or Gastro-oesophageal Junction, Cancer","enrollment":39},{"nctId":"NCT01284595","phase":"PHASE1","title":"Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-03","conditions":"Healthy","enrollment":6},{"nctId":"NCT01151215","phase":"PHASE2","title":"Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Neoplasms, Breast Neoplasms, Breast Cancer","enrollment":482},{"nctId":"NCT01003158","phase":"PHASE1","title":"Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Neoplasms, Metastatic Cancer, Breast Cancer","enrollment":17},{"nctId":"NCT00637039","phase":"PHASE1","title":"Study of AZD8931 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Advanced Solid Malignancies","enrollment":41},{"nctId":"NCT01596530","phase":"PHASE1","title":"Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Breast Neoplasm","enrollment":3},{"nctId":"NCT01330758","phase":"PHASE1","title":"A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-04","conditions":"Healthy","enrollment":26},{"nctId":"NCT00879346","phase":"PHASE1","title":"A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD8931","genericName":"AZD8931","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD8931 is a PI3K inhibitor. Used for Advanced solid tumours.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}